Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains an important public health problem being one of the top ten causes of death worldwide. In many countries where TB is endemic, the diagnosis of pulmonary TB is mostly dependent of sputum smear microscopy by Mtb acid-fast staining or culture, which present low sensitivity or is time-consuming. Therefore, the World Health Organization (WHO) identified the need of a non-sputum and a rapid biomarker-based test as a high-priority for TB diagnosis. In a previous study, our research group applied an immune-based gene expression profile by NanoString platform and identified 23 genes associated with inflammatory mechanisms. The expression of these genes was able to distinguish, with high sensitivity and specificity, individuals with TB from those with other pulmonary diseases (OPD). Thus, in this study, we applied the RT-qPCR assay to evaluate the diagnostic power of the genes FCGR1A, GBP5, IRAK3, PDCD1LG2, MAPK14, CD274, CD59, ICAM1, IFITM1, PML, C1QA and CR1 in whole blood-based samples from nine healthy individuals (HC) and ten individuals with pulmonary TB. Preliminary analysis showed differences in the expression levels of FCGR1A, GBP5, IRAK3, and PDCD1LG2 genes between TB and HC groups. Receiver Operating Characteristic (ROC) curve analysis revealed that the area under the curve (AUC), sensitivities and specificities were, respectively, 0.93 (95% CI 0.81–1.00), 88.89% (56,50-99,43), and 90% (59,58–99,49) for FCGR1A and 0.83 (95% CI 0.64–1.00), 66,67% (35,42–87,94) and 90% (59,58–99,49) for GBP5. FCGR1A and GBP5 genes stood out as potential markers for TB diagnosis as they were able to discriminate individuals with TB from HC.